当前位置: X-MOL 学术Int. Clinical Psychopharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Benefit of long-acting paliperidone in Huntington's disease: a case report.
International Clinical Psychopharmacology ( IF 2.1 ) Pub Date : 2021-03-01 , DOI: 10.1097/yic.0000000000000346
Hervé Javelot 1, 2 , Mylène Meyer 3, 4 , Solène Frismand 3, 4 , Coraline Hingray 3, 5
Affiliation  

Through this brief report, we described our clinical considerations about the treatment of motor fluctuations and psychiatric comorbidities in Huntington's disease, for example, aggressiveness and obsessive-compulsive disorders. Indeed, as classical treatment, for example, olanzapine and risperidone, were inefficient to improve motor disorders in our patient, we postulated that motor fluctuations could be influenced by the pharmacokinetic profile of oral risperidone. So, in line with recent practice in schizophrenia, we proposed empirically paliperidone 1-month long-acting injections hypothesized to improve motor fluctuations, treatment so far reserved to Huntington's disease patients who are noncompliant to oral risperidone. Improvement was soon observed concerning motor fluctuations, but also aggressiveness, supporting our initial hypothesis.

中文翻译:

长效帕潘立酮对亨廷顿病的益处:病例报告。

通过这份简短的报告,我们描述了我们对治疗亨廷顿病的运动波动和精神共病的临床考虑,例如攻击性和强迫症。事实上,由于经典治疗,例如奥氮平和利培酮,对改善我们患者的运动障碍无效,我们假设运动波动可能受到口服利培酮的药代动力学特征的影响。因此,根据最近在精神分裂症中的实践,我们根据经验提出了帕潘立酮 1 个月长效注射剂,假设可以改善运动波动,到目前为止,治疗仅限于对口服利培酮不依从的亨廷顿病患者。很快就观察到运动波动的改善,但也有攻击性,
更新日期:2021-03-01
down
wechat
bug